# Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Study · id `cardio:ct-nct03604198` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03604198](<https://clinicaltrials.gov/study/NCT03604198>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT03604198

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 125 participants.

## Technical summary

Registry record NCT03604198. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-07 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 125 participants (enrolled count; ClinicalTrials.gov record NCT03604198, source copy `cardio:ctgov-nct03604198-2026-11-03`, retrieved 2026-11-18)
- Started: 2018-05-07 (actual) (ClinicalTrials.gov record NCT03604198, source copy `cardio:ctgov-nct03604198-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT03604198, source copy `cardio:ctgov-nct03604198-2026-11-03`, retrieved 2026-11-18)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT03604198, source copy `cardio:ctgov-nct03604198-2026-11-03`, retrieved 2026-11-18)
- Countries: United States; Austria; Canada; Germany; Israel; Italy; Netherlands; Poland; Romania; Spain (ClinicalTrials.gov record NCT03604198, source copy `cardio:ctgov-nct03604198-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03604198-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
- Condition: Cushing Syndrome
- Intervention (Drug): relacorilant
- Lead sponsor: Corcept Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Corcept Therapeutics (`cardio:org-corcept-therapeutics`)

## Provenance

Content hash: c6ce9352e18b535516f7cd5dc1d31d58113784a2700d1622b36eb9a1ebe94872
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
